Press Releases
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
Los Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position, Mr. Ford will be responsible for growing Endonovo’s pipeline of marketing, content and thought leadership strategies.
Mr. Ford has 25 years of surgical device commercial experience with leading companies, including Allergan, Ethicon, Bard & Baxter. Most recently, Mr. Ford was the U.S. Vice President of Marketing for Biom’up, where he launched the surgical hemostat HEMOBLAST Bellows™. Steven’s career includes the launch of over 50 medical devices globally as well as having participated and led over 75 product development teams. Steven holds a B.S. in Marketing from California State University.
Alan Collier, Endonovo’s Chief Executive Officer, stated, "The addition of Steven to our senior management group will help us develop alliances critical in the medical community. Steven has a very successful track record as a marketing leader in the medical device world and his knowledge and experience will bring a new perspective to our vision of leveraging our healthcare advantages for the future of SofPulse.”
“Steven’s combination of medical device expertise, industry relationships, and business development experience will build upon an existing strong foundation and accelerate global adoption of SofPulse,” concluded Mr. Collier.
Steven Ford stated, "I am extremely excited to join the Endonovo team. SofPulse is an amazing technology and well positioned to become the new standard of care for post-surgical pain as a viable alternative to opioids. I look forward to introducing physicians and patients to this revolutionary technology."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Logo.jpg
Source: Endonovo Therapeutics, Inc.
Released May 7, 2019
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
Los Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position, Mr. Ford will be responsible for growing Endonovo’s pipeline of marketing, content and thought leadership strategies.
Mr. Ford has 25 years of surgical device commercial experience with leading companies, including Allergan, Ethicon, Bard & Baxter. Most recently, Mr. Ford was the U.S. Vice President of Marketing for Biom’up, where he launched the surgical hemostat HEMOBLAST Bellows™. Steven’s career includes the launch of over 50 medical devices globally as well as having participated and led over 75 product development teams. Steven holds a B.S. in Marketing from California State University.
Alan Collier, Endonovo’s Chief Executive Officer, stated, "The addition of Steven to our senior management group will help us develop alliances critical in the medical community. Steven has a very successful track record as a marketing leader in the medical device world and his knowledge and experience will bring a new perspective to our vision of leveraging our healthcare advantages for the future of SofPulse.”
“Steven’s combination of medical device expertise, industry relationships, and business development experience will build upon an existing strong foundation and accelerate global adoption of SofPulse,” concluded Mr. Collier.
Steven Ford stated, "I am extremely excited to join the Endonovo team. SofPulse is an amazing technology and well positioned to become the new standard of care for post-surgical pain as a viable alternative to opioids. I look forward to introducing physicians and patients to this revolutionary technology."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Logo.jpg
Source: Endonovo Therapeutics, Inc.
Released May 7, 2019
